How to manage recurrences after surgery in CRSwNP patients in the biologic era: a narrative review.

Authors:
De Corso E; Settimi S; Montuori C; Cantiani A; Corbò M and 7 more

Journal:
Acta Otorhinolaryngol Ital

Publication Year: 2023

DOI:
10.14639/0392-100X-suppl.1-43-2023-01

PMCID:
PMC10159635

PMID:
37698095

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Acta Otorhinolaryngol Ital

Abbreviation: Acta Otorhinolaryngol Ital

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Otorhinolaryngology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Extended cervical approach for retrosternal multinodular goiter.
Tsur N; Levi L; Frig O and 9 more (2024) - Transparency Score: 3/6
Management of nasal vestibule carcinomas: recommendations by the Oncological Committee of the Itali…
Bussu F; Tagliaferri L; Corbisiero MF and 13 more (2024) - Transparency Score: 3/6
Angiotensin-converting enzyme insertion/deletion gene polymorphism in patients with laryngeal cance…
Kumbul YÇ; Hekimler Öztürk K; Yasan H and 3 more (2023) - Transparency Score: 3/6
Artificial intelligence for the recognition of benign lesions of vocal folds from audio recordings.
Marchese MR; Sensoli F; Campagnini S and 8 more (2023) - Transparency Score: 3/6
Assessment of middle ear function after conventional or endoscopic microdebrider assisted adenoidec…
Giri O; Shenoy SV; Parvathareddy N and 3 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest statement EDC: participations in experts board meeting of GSK, Novartis, Sanofi, Astrazeneca. SS: participations in experts board meeting of GSK. CM, AC, MC, GADB, FS, FP, MR, GCP, JG: none."

Evidence found in paper:

"This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025